Supporting Information
Published: 2 March 2023| Version 1 | DOI: 10.17632/jk9d6zhrtr.1
Contributor:
Description
Table S1. Patient-reported side effects Table S2. Baseline and follow-up scores in our daily practice cohort, limited daily practice literature and clinical trials (dupilumab (Q2W) treatment) Figure S1. Estimated mean change in Dermatology Life Quality Index (DLQI) scores in patients with atopic dermatitis from start until 16 weeks of dupilumab treatment (n=95) Figure S2. Investigator Global Assessment (IGA) scores at baseline and follow-up ( between 12 and 16 weeks) Appendix 1 - Criteria for dupilumab treatment set forth by the Dutch Society of Dermatology (NVDV) Appendix 2 – Histograms, Akaike Information Criterion (AIC) of original and sqrt-transformed scale
Files
Institutions
Universiteit van Amsterdam
Categories
Systemic Treatment, Atopic Dermatitis, Patient Registry